{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:06:08Z","timestamp":1792292768071,"version":"4.4.0"},"reference-count":181,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,15]],"date-time":"2015-10-15T00:00:00Z","timestamp":1444867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,10,15]],"date-time":"2015-10-15T00:00:00Z","timestamp":1444867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Dis Primers"],"DOI":"10.1038\/nrdp.2015.56","type":"journal-article","created":{"date-parts":[[2015,10,15]],"date-time":"2015-10-15T06:44:14Z","timestamp":1444891454000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1686,"title":["Alzheimer's disease"],"prefix":"10.1038","volume":"1","author":[{"given":"Colin L.","family":"Masters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa A.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,15]]},"reference":[{"key":"BFnrdp201556_CR1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1212\/WNL.43.3_Part_1.515","volume":"43","author":"DL Bachman","year":"1993","unstructured":"Bachman, D. L. et al. Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study. Neurology 43, 515\u2013519 (1993).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR2","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jama.1995.03520410048025","volume":"273","author":"LE Hebert","year":"1995","unstructured":"Hebert, L. E. et al. Age-specific incidence of Alzheimer's disease in a community population. JAMA 273, 1354\u20131359 (1995).","journal-title":"JAMA"},{"key":"BFnrdp201556_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/archneur.60.2.185","volume":"60","author":"DA Evans","year":"2003","unstructured":"Evans, D. A. et al. Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status. Arch. Neurol. 60, 185\u2013189 (2003).","journal-title":"Arch. Neurol."},{"key":"BFnrdp201556_CR4","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1212\/WNL.54.11.2072","volume":"54","author":"C Kawas","year":"2000","unstructured":"Kawas, C., Gray, S., Brookmeyer, R., Fozard, J. & Zonderman, A. Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 54, 2072\u20132077 (2000). The Baltimore longitudinal study has a good chance of determining the true incidence of Alzheimer's disease.","journal-title":"Neurology"},{"key":"BFnrdp201556_CR5","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1093\/brain\/awr053","volume":"134","author":"PT Nelson","year":"2011","unstructured":"Nelson, P. T. et al. Hippocampal sclerosis in advanced age: clinical and pathological features. Brain 134, 1506\u20131518 (2011).","journal-title":"Brain"},{"key":"BFnrdp201556_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/ageing\/aft091","volume":"43","author":"GW Duncan","year":"2014","unstructured":"Duncan, G. W. et al. The incidence of Parkinson's disease in the north-east of England. Age Ageing 43, 257\u2013263 (2014).","journal-title":"Age Ageing"},{"key":"BFnrdp201556_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.parkreldis.2013.01.014","volume":"19","author":"R Caslake","year":"2013","unstructured":"Caslake, R. et al. Age-, gender-, and socioeconomic status-specific incidence of Parkinson's disease and parkinsonism in northeast Scotland: the PINE study. Parkinsonism Relat. Disord. 19, 515\u2013521 (2013).","journal-title":"Parkinsonism Relat. Disord."},{"key":"BFnrdp201556_CR8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1001\/jamaneurol.2013.114","volume":"70","author":"R Savica","year":"2013","unstructured":"Savica, R., Grossardt, B. R., Bower, J. H., Ahlskog, J. E. & Rocca, W. A. Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurol. 70, 859\u2013866 (2013).","journal-title":"JAMA Neurol."},{"key":"BFnrdp201556_CR9","unstructured":"Australian Bureau of Statistics. Causes of death, Australia, 2013. ABS[online], (2015)."},{"key":"BFnrdp201556_CR10","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1001\/jama.2015.4669","volume":"313","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele, R. et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA 313, 1939\u20131949 (2015).","journal-title":"JAMA"},{"key":"BFnrdp201556_CR11","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2015","unstructured":"Jansen, W. J. et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313, 1924\u20131938 (2015).","journal-title":"JAMA"},{"key":"BFnrdp201556_CR12","unstructured":"Prince, M. et al. World Alzheimer Report 2015. Alzheimer's Disease International[online], (2015)."},{"key":"BFnrdp201556_CR13","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S1474-4422(14)70136-X","volume":"13","author":"S Norton","year":"2014","unstructured":"Norton, S., Matthews, F. E., Barnes, D. E., Yaffe, K. & Brayne, C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 13, 788\u2013794 (2014).","journal-title":"Lancet Neurol."},{"key":"BFnrdp201556_CR14","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","volume":"385","author":"T Ngandu","year":"2015","unstructured":"Ngandu, T. et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385, 2255\u20132263 (2015).","journal-title":"Lancet"},{"key":"BFnrdp201556_CR15","unstructured":"Prince, M., Albanese, E., Guerchet, M. & Prina, M. World Alzheimer Report 2014. Alzheimer's Disease International[online], (2014). An excellent overview of the current evidence of environmental influences on dementia and Alzheimer's disease."},{"key":"BFnrdp201556_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S0925-4439(00)00043-0","volume":"1502","author":"TE Golde","year":"2000","unstructured":"Golde, T. E., Eckman, C. B. & Younkin, S. G. Biochemical detection of A\u03b2 isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim. Biophys. Acta 1502, 172\u2013187 (2000).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrdp201556_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1152\/physrev.2001.81.2.741","volume":"81","author":"DJ Selkoe","year":"2001","unstructured":"Selkoe, D. J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741\u2013766 (2001).","journal-title":"Physiol. Rev."},{"key":"BFnrdp201556_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00401-010-0690-1","volume":"120","author":"E Portelius","year":"2010","unstructured":"Portelius, E. et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol. 120, 185\u2013193 (2010).","journal-title":"Acta Neuropathol."},{"key":"BFnrdp201556_CR19","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0169-409X(02)00158-8","volume":"54","author":"DM Holtzman","year":"2002","unstructured":"Holtzman, D. M., Bales, K. R., Paul, S. M. & DeMattos, R. B. A\u03b2 immunization and anti-A\u03b2 antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Adv. Drug Deliv. Rev. 54, 1603\u20131613 (2002).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"BFnrdp201556_CR20","first-page":"S88","volume":"70","author":"RE Potter","year":"2011","unstructured":"Potter, R. E. et al. Amyloid-beta 42:40 metabolism is altered in autosomal dominant Alzheimer's disease (ADAD). Ann. Neurol. 70, S88\u2013S89 (2011).","journal-title":"Ann. Neurol."},{"key":"BFnrdp201556_CR21","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner, D. et al. Secreted amyloid \u03b2-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 2, 864\u2013870 (1996).","journal-title":"Nat. Med."},{"key":"BFnrdp201556_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.nbd.2004.04.018","volume":"17","author":"S Hecimovic","year":"2004","unstructured":"Hecimovic, S. et al. Mutations in APP have independent effects on A\u03b2 and CTF\u03b3 generation. Neurobiol. Dis. 17, 205\u2013218 (2004).","journal-title":"Neurobiol. Dis."},{"key":"BFnrdp201556_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/humu.20336","volume":"27","author":"S Kumar-Singh","year":"2006","unstructured":"Kumar-Singh, S. et al. Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased A\u03b242 and decreased A\u03b240. Hum. Mutat. 27, 686\u2013695 (2006).","journal-title":"Hum. Mutat."},{"key":"BFnrdp201556_CR24","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795\u2013804 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrdp201556_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1212\/WNL.0000000000000596","volume":"83","author":"DC Ryman","year":"2014","unstructured":"Ryman, D. C. et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 83, 253\u2013260 (2014).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/hmg\/ddh019","volume":"13","author":"JL Jankowsky","year":"2004","unstructured":"Jankowsky, J. L. et al. Mutant presenilins specifically elevate the levels of the 42 residue \u03b2-amyloid peptide in vivo: evidence for augmentation of a 42-specific \u03b3 secretase. Hum. Mol. Genet. 13, 159\u2013170 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrdp201556_CR27","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0896-6273(00)80230-5","volume":"17","author":"DR Borchelt","year":"1996","unstructured":"Borchelt, D. R. et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate A\u03b21\u201342\/1\u201340 ratio in vitro and in vivo. Neuron 17, 1005\u20131013 (1996).","journal-title":"Neuron"},{"key":"BFnrdp201556_CR28","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1093\/brain\/122.9.1709","volume":"122","author":"T Gomez-Isla","year":"1999","unstructured":"Gomez-Isla, T. et al. The impact of different presenilin 1 and presenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain \u2014 evidence for other phenotype-modifying factors. Brain 122, 1709\u20131719 (1999).","journal-title":"Brain"},{"key":"BFnrdp201556_CR29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ana.410170310","volume":"17","author":"KE Wisniewski","year":"1985","unstructured":"Wisniewski, K. E., Wisniewski, H. M. & Wen, G. Y. Occurrence of neuropathological changes and dementia of Alzheimers-disease in Down syndrome. Ann. Neurol. 17, 278\u2013282 (1985).","journal-title":"Ann. Neurol."},{"key":"BFnrdp201556_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature11283","volume":"488","author":"T Jonsson","year":"2012","unstructured":"Jonsson, T. et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96\u201399 (2012).","journal-title":"Nature"},{"key":"BFnrdp201556_CR31","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/nm1438","volume":"12","author":"RJ Bateman","year":"2006","unstructured":"Bateman, R. J. et al. Human amyloid-\u03b2 synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12, 856\u2013861 (2006).","journal-title":"Nat. Med."},{"key":"BFnrdp201556_CR32","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1126\/science.1197623","volume":"330","author":"KG Mawuenyega","year":"2010","unstructured":"Mawuenyega, K. G. et al. Decreased clearance of CNS \u03b2-amyloid in Alzheimer's disease. Science 330, 1774\u20131774 (2010).","journal-title":"Science"},{"key":"BFnrdp201556_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.21623","volume":"66","author":"RJ Bateman","year":"2009","unstructured":"Bateman, R. J. et al. A \u03b3-secretase inhibitor decreases amyloid-\u03b2 production in the central nervous system. Ann. Neurol. 66, 48\u201354 (2009).","journal-title":"Ann. Neurol."},{"key":"BFnrdp201556_CR34","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0006-8993(91)91092-F","volume":"541","author":"Y Namba","year":"1991","unstructured":"Namba, Y., Tomonaga, M., Kawasaki, H., Otomo, E. & Ikeda, K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimers disease and kuru plaque amyloid in Creutzfeldt\u2013Jakob disease. Brain Res. 541, 163\u2013166 (1991).","journal-title":"Brain Res."},{"key":"BFnrdp201556_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0014-5793(97)01543-3","volume":"421","author":"MJ Artiga","year":"1998","unstructured":"Artiga, M. J. et al. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett. 421, 105\u2013108 (1998).","journal-title":"FEBS Lett."},{"key":"BFnrdp201556_CR36","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1212\/WNL.43.8.1467","volume":"43","author":"AM Saunders","year":"1993","unstructured":"Saunders, A. M. et al. Association of apolipoprotein E allele \u03b54 with late-onset familial and sporadic Alzheimers disease. Neurology 43, 1467\u20131472 (1993).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1385\/JMN:23:3:189","volume":"23","author":"YD Huang","year":"2004","unstructured":"Huang, Y. D., Weisgraber, K. H., Mucke, L. & Mahley, R. W. Apolipoprotein E: diversity of cellular origins, structural and biophysical properties, and effects in Alzheimer's disease. J. Mol. Neurosci. 23, 189\u2013204 (2004).","journal-title":"J. Mol. Neurosci."},{"key":"BFnrdp201556_CR38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1399-0012.1997.tb00827.x","volume":"11","author":"C Fern\u00e1ndez-Miranda","year":"1997","unstructured":"Fern\u00e1ndez-Miranda, C. et al. Changes in phenotypes of apolipoprotein E and apolipoprotein(a) in liver transplant recipients. Clin. Transplant. 11, 325\u2013327 (1997).","journal-title":"Clin. Transplant."},{"key":"BFnrdp201556_CR39","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jama.1997.03550160069041","volume":"278","author":"LA Farrer","year":"1997","unstructured":"Farrer, L. A. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease \u2014 a meta-analysis. JAMA 278, 1349\u20131356 (1997).","journal-title":"JAMA"},{"key":"BFnrdp201556_CR40","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder, E. H. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimers-disease in late-onset families. Science 261, 921\u2013923 (1993). The first identification of the main genetic risk factor in sporadic and late-onset familial Alzheimer's disease.","journal-title":"Science"},{"key":"BFnrdp201556_CR41","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/archpsyc.61.5.518","volume":"61","author":"AS Khachaturian","year":"2004","unstructured":"Khachaturian, A. S. et al. Apolipoprotein E \u03b54 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: the Cache County Study. Arch. Gen. Psychiatry 61, 518\u2013524 (2004).","journal-title":"Arch. Gen. Psychiatry"},{"key":"BFnrdp201556_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng0694-180","volume":"7","author":"EH Corder","year":"1994","unstructured":"Corder, E. H. et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7, 180\u2013184 (1994).","journal-title":"Nat. Genet."},{"key":"BFnrdp201556_CR43","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1002\/ana.24369","volume":"77","author":"A Serrano-Pozo","year":"2015","unstructured":"Serrano-Pozo, A., Qian, J., Monsell, S. E., Betensky, R. A. & Hyman, B. T. APOE\u03b52 is associated with milder clinical and pathological Alzheimer disease. Ann. Neurol. 77, 917\u2013929 (2015).","journal-title":"Ann. Neurol."},{"key":"BFnrdp201556_CR44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1385\/JMN:23:3:157","volume":"23","author":"JW Ashford","year":"2004","unstructured":"Ashford, J. W. APOE genotype effects on Alzheimer's disease onset and epidemiology. J. Mol. Neurosci. 23, 157\u2013165 (2004).","journal-title":"J. Mol. Neurosci."},{"key":"BFnrdp201556_CR45","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1385\/JMN:23:3:247","volume":"23","author":"DM Holtzman","year":"2004","unstructured":"Holtzman, D. M. In vivo effects of ApoE and clusterin on amyloid-\u03b2 metabolism and neuropathology. J. Mol. Neurosci. 23, 247\u2013254 (2004).","journal-title":"J. Mol. Neurosci."},{"key":"BFnrdp201556_CR46","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1073\/pnas.050004797","volume":"97","author":"DM Holtzman","year":"2000","unstructured":"Holtzman, D. M. et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 97, 2892\u20132897 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrdp201556_CR47","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1172\/JCI6179","volume":"103","author":"DM Holtzman","year":"1999","unstructured":"Holtzman, D. M. et al. Expression of human apolipoprotein E reduces amyloid-\u03b2 deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 103, R15\u2013R21 (1999).","journal-title":"J. Clin. Invest."},{"key":"BFnrdp201556_CR48","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0896-6273(03)00850-X","volume":"41","author":"RB DeMattos","year":"2004","unstructured":"DeMattos, R. B. et al. ApoE and clusterin cooperatively suppress A\u03b2 levels and deposition: evidence that ApoE regulates extracellular A\u03b2 metabolism in vivo. Neuron 41, 193\u2013202 (2004).","journal-title":"Neuron"},{"key":"BFnrdp201556_CR49","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1073\/pnas.90.5.1977","volume":"90","author":"WJ Strittmatter","year":"1993","unstructured":"Strittmatter, W. J. et al. Apolipoprotein E: high-avidity binding to \u03b2-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 1977\u20131981 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrdp201556_CR50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1385\/JMN:17:2:147","volume":"17","author":"DM Holtzman","year":"2001","unstructured":"Holtzman, D. M. Role of apoE\/A\u03b2 interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. J. Mol. Neurosci. 17, 147\u2013155 (2001).","journal-title":"J. Mol. Neurosci."},{"key":"BFnrdp201556_CR51","doi-asserted-by":"publisher","first-page":"15233","DOI":"10.1073\/pnas.96.26.15233","volume":"96","author":"KR Bales","year":"1999","unstructured":"Bales, K. R. et al. Apolipoprotein E is essential for amyloid deposition in the APPV717F transgenic mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 96, 15233\u201315238 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrdp201556_CR52","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1172\/JCI10498","volume":"106","author":"M Shibata","year":"2000","unstructured":"Shibata, M. et al. Clearance of Alzheimer's amyloid-\u03b21\u201340 peptide from brain by LDL receptor-related protein-1 at the blood\u2013brain barrier. J. Clin. Invest. 106, 1489\u20131499 (2000).","journal-title":"J. Clin. Invest."},{"key":"BFnrdp201556_CR53","doi-asserted-by":"publisher","first-page":"8838","DOI":"10.1073\/pnas.151254698","volume":"98","author":"YD Huang","year":"2001","unstructured":"Huang, Y. D. et al. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc. Natl Acad. Sci. USA 98, 8838\u20138843 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrdp201556_CR54","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.8171342","volume":"264","author":"BP Nathan","year":"1994","unstructured":"Nathan, B. P. et al. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264, 850\u2013852 (1994).","journal-title":"Science"},{"key":"BFnrdp201556_CR55","doi-asserted-by":"publisher","first-page":"19791","DOI":"10.1074\/jbc.270.34.19791","volume":"270","author":"BP Nathan","year":"1995","unstructured":"Nathan, B. P. et al. The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization. J. Biol. Chem. 270, 19791\u201319799 (1995).","journal-title":"J. Biol. Chem."},{"key":"BFnrdp201556_CR56","doi-asserted-by":"publisher","first-page":"27063","DOI":"10.1074\/jbc.270.45.27063","volume":"270","author":"S Bellosta","year":"1995","unstructured":"Bellosta, S. et al. Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth. J. Biol. Chem. 270, 27063\u201327071 (1995).","journal-title":"J. Biol. Chem."},{"key":"BFnrdp201556_CR57","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1172\/JCI36663","volume":"118","author":"R Deane","year":"2008","unstructured":"Deane, R. et al. ApoE isoform-specific disruption of amyloid \u03b2 peptide clearance from mouse brain. J. Clin. Invest. 118, 4002\u20134013 (2008).","journal-title":"J. Clin. Invest."},{"key":"BFnrdp201556_CR58","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1006\/nbdi.1997.0147","volume":"4","author":"T Wisniewski","year":"1997","unstructured":"Wisniewski, T., Ghiso, J. & Frangione, B. Biology of A\u03b2 amyloid in Alzheimer's disease. Neurobiol. Dis. 4, 313\u2013328 (1997).","journal-title":"Neurobiol. Dis."},{"key":"BFnrdp201556_CR59","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan, A. M. et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A\u03b242 in humans. Ann. Neurol. 59, 512\u2013519 (2006).","journal-title":"Ann. Neurol."},{"key":"BFnrdp201556_CR60","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1212\/WNL.56.9.1143","volume":"56","author":"DS Knopman","year":"2001","unstructured":"Knopman, D. S. et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1143\u20131153 (2001).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR61","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway, S. et al. Two Phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 322\u2013333 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrdp201556_CR62","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0960-894X(01)00734-X","volume":"12","author":"CA Mathis","year":"2002","unstructured":"Mathis, C. A. et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg. Med. Chem. Lett. 12, 295\u2013298 (2002). This study is the beginning of the molecular PET imaging revolution for Alzheimer's disease.","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"BFnrdp201556_CR63","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk, W. E. et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 55, 306\u2013319 (2004). This landmark paper by William Klunk (co-developer of PiB with his colleague Chet Mathis at the University of Pittsburg, Pennsylvania, USA) marked the beginning of A\u03b2 PET imaging in humans. The paper included the method and showed the distribution of A\u03b2 plaques in patients with Alzheimer's disease from a global 3D brain perspective.","journal-title":"Ann. Neurol."},{"key":"BFnrdp201556_CR64","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","volume":"67","author":"MA Mintun","year":"2006","unstructured":"Mintun, M. A. et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67, 446\u2013452 (2006).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR65","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1212\/01.wnl.0000261919.22630.ea","volume":"68","author":"CC Rowe","year":"2007","unstructured":"Rowe, C. C. et al. Imaging \u03b2-amyloid burden in aging and dementia. Neurology 68, 1718\u20131725 (2007).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR66","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/archneurol.2009.269","volume":"66","author":"JC Morris","year":"2009","unstructured":"Morris, J. C. et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 66, 1469\u20131475 (2009).","journal-title":"Arch. Neurol."},{"key":"BFnrdp201556_CR67","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1212\/WNL.0b013e3182563bbe","volume":"78","author":"DS Knopman","year":"2012","unstructured":"Knopman, D. S. et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 78, 1576\u20131582 (2012).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR68","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/ana.24040","volume":"74","author":"CC Rowe","year":"2013","unstructured":"Rowe, C. C. et al. Predicting Alzheimer disease with \u03b2-amyloid imaging: results from the Australian Imaging, Biomarkers, and Lifestyle Study of Ageing. Ann. Neurol. 74, 905\u2013913 (2013).","journal-title":"Ann. Neurol."},{"key":"BFnrdp201556_CR69","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne, V. L. et al. Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12, 357\u2013367 (2013). Using longitudinal imaging with 11C -PiB PET, the authors demonstrated the rate of A\u03b2 accummulation, establishing that it takes up to 30 years to reach the level found on average in patients with mild Alzheimer's disease. It also demonstrated that A\u03b2 PET scans showed abnormalities a decade or more before measures of hippocampal volume and cognition became abnormal. This work supported the concept of preclinical Alzheimer's disease and identified a wide time window for early intervention to potentially prevent dementia in those developing Alzheimer's disease.","journal-title":"Lancet Neurol."},{"key":"BFnrdp201556_CR70","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0b013e3182840bbe","volume":"80","author":"CR Jack Jr","year":"2013","unstructured":"Jack, C. R. Jr et al. Brain \u03b2-amyloid load approaches a plateau. Neurology 80, 890\u2013896 (2013).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR71","doi-asserted-by":"publisher","unstructured":"Lim, Y. Y. et al. APOE and BDNF polymorphisms moderate amyloid beta-related cognitive decline in preclinical Alzheimer's disease. Mol. Psychiatry http:\/\/dx.doi.org\/10.1038\/mp.2014.123 (2015). The interaction of gene polymorphisms and Alzheimer's disease-related pathology on the progression rates for clinical and cognitive decline is an emerging area that will have implications for individual prognosis and therapy trial design. This prospective observational study confirmed earlier reports of stable memory function in older healthy people with negative A\u03b2 PET scans compared with a slow but significant decline in those who had positive A\u03b2 PET scans; this decline was much faster in APOE4 carriers and even worse in those who also carried the brain-derived neurotrophic factor (BDNF)Val\/Met allele.","DOI":"10.1038\/mp.2014.123"},{"key":"BFnrdp201556_CR72","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00259-012-2237-2","volume":"40","author":"A Nordberg","year":"2013","unstructured":"Nordberg, A. et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 40, 104\u2013114 (2013).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"BFnrdp201556_CR73","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/jnnp-2014-308094","volume":"86","author":"KT Ong","year":"2014","unstructured":"Ong, K. T. et al. A\u03b2 imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. J. Neurol. Neurosurg. Psychiatry 86, 431\u2013436 (2014).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrdp201556_CR74","doi-asserted-by":"publisher","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","volume":"6","author":"RA Sperling","year":"2014","unstructured":"Sperling, R. A. et al. The A4 study: stopping AD before symptoms begin? Sci. Transl. Med. 6, 228fs13 (2014).","journal-title":"Sci. Transl. Med."},{"key":"BFnrdp201556_CR75","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging\u2013Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280\u2013292 (2011).","journal-title":"Alzheimers Dement."},{"key":"BFnrdp201556_CR76","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert, M. S. et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging\u2013Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 270\u2013279 (2011).","journal-title":"Alzheimers Dement."},{"key":"BFnrdp201556_CR77","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois, B. et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 13, 614\u2013629 (2014). An important review of the evolving diagnostic criteria for Alzheimer's disease.","journal-title":"Lancet Neurol."},{"key":"BFnrdp201556_CR78","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","volume":"64","author":"AM Fagan","year":"2007","unstructured":"Fagan, A. M. et al. Cerebrospinal fluid tau\/\u03b2-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 64, 343\u2013349 (2007).","journal-title":"Arch. Neurol."},{"key":"BFnrdp201556_CR79","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00401-013-1151-4","volume":"126","author":"JB Toledo","year":"2013","unstructured":"Toledo, J. B., Xie, S. X., Trojanowski, J. Q. & Shaw, L. M. Longitudinal change in CSF tau and A\u03b2 biomarkers for up to 48 months in ADNI. Acta Neuropathol. 126, 659\u2013670 (2013).","journal-title":"Acta Neuropathol."},{"key":"BFnrdp201556_CR80","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jamaneurol.2014.1358","volume":"71","author":"S Palmqvist","year":"2014","unstructured":"Palmqvist, S. et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid \u03b2-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 71, 1282\u20131289 (2014).","journal-title":"JAMA Neurol."},{"key":"BFnrdp201556_CR81","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/brain\/awu367","volume":"138","author":"N Mattsson","year":"2015","unstructured":"Mattsson, N. et al. Independent information from cerebrospinal fluid amyloid-\u03b2 and florbetapir imaging in Alzheimer's disease. Brain 138, 772\u2013783 (2015).","journal-title":"Brain"},{"key":"BFnrdp201556_CR82","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1474-4422(08)70001-2","volume":"7","author":"CC Rowe","year":"2008","unstructured":"Rowe, C. C. et al. Imaging of amyloid \u03b2 in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 7, 129\u2013135 (2008).","journal-title":"Lancet Neurol."},{"key":"BFnrdp201556_CR83","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","volume":"11","author":"CM Clark","year":"2012","unstructured":"Clark, C. M. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol. 11, 669\u2013678 (2012).","journal-title":"Lancet Neurol."},{"key":"BFnrdp201556_CR84","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","volume":"72","author":"C Curtis","year":"2015","unstructured":"Curtis, C. et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 72, 287\u2013294 (2015).","journal-title":"JAMA Neurol."},{"key":"BFnrdp201556_CR85","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","volume":"3","author":"O Sabri","year":"2015","unstructured":"Sabri, O., Seibyl, J., Rowe, C. & Barthel, H. Beta-amyloid imaging with florbetaben. Clin. Transl. Imaging 3, 13\u201326 (2015).","journal-title":"Clin. Transl. Imaging"},{"key":"BFnrdp201556_CR86","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1474-4422(14)70252-2","volume":"14","author":"VL Villemagne","year":"2015","unstructured":"Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L. & Rowe, C. C. Tau imaging: early progress and future directions. Lancet Neurol. 14, 114\u2013124 (2015).","journal-title":"Lancet Neurol."},{"key":"BFnrdp201556_CR87","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1017\/S1041610209009405","volume":"21","author":"KA Ellis","year":"2009","unstructured":"Ellis, K. A. et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int. Psychogeriatr. 21, 672\u2013687 (2009).","journal-title":"Int. Psychogeriatr."},{"key":"BFnrdp201556_CR88","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131\u2013144 (2010).","journal-title":"Nat. Rev. Neurol."},{"key":"BFnrdp201556_CR89","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","volume":"60","author":"D Strozyk","year":"2003","unstructured":"Strozyk, D., Blennow, K., White, L. R. & Launer, L. J. CSF A\u03b242 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60, 652\u2013656 (2003).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR90","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/acn3.81","volume":"1","author":"N Mattsson","year":"2014","unstructured":"Mattsson, N. et al. Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Ann. Clin. Transl. Neurol. 1, 534\u2013543 (2014).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"BFnrdp201556_CR91","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1212\/WNL.0b013e3181dd4dd8","volume":"74","author":"AK Wallin","year":"2010","unstructured":"Wallin, A. K. et al. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 74, 1531\u20131537 (2010).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR92","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/sj.mp.4001220","volume":"8","author":"M Riemenschneider","year":"2003","unstructured":"Riemenschneider, M. et al. Phospho-tau\/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt\u2013Jakob disease from other dementias. Mol. Psychiatry 8, 343\u2013347 (2003).","journal-title":"Mol. Psychiatry"},{"key":"BFnrdp201556_CR93","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1373\/clinchem.2008.104497","volume":"54","author":"JM Lee","year":"2008","unstructured":"Lee, J. M. et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin. Chem. 54, 1617\u20131623 (2008).","journal-title":"Clin. Chem."},{"key":"BFnrdp201556_CR94","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1212\/WNL.0000000000001015","volume":"83","author":"T Skillback","year":"2014","unstructured":"Skillback, T. et al. CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 83, 1945\u20131953 (2014).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR95","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1074\/jbc.M111.277061","volume":"287","author":"S Saman","year":"2012","unstructured":"Saman, S. et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem. 287, 3842\u20133849 (2012).","journal-title":"J. Biol. Chem."},{"key":"BFnrdp201556_CR96","doi-asserted-by":"publisher","first-page":"194re2","DOI":"10.1126\/scitranslmed.3006446","volume":"5","author":"LF Maia","year":"2013","unstructured":"Maia, L. F. et al. Changes in amyloid-\u03b2 and tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci. Transl. Med. 5, 194re2 (2013).","journal-title":"Sci. Transl. Med."},{"key":"BFnrdp201556_CR97","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/brain\/awl269","volume":"129","author":"K Buerger","year":"2006","unstructured":"Buerger, K. et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129, 3035\u20133041 (2006).","journal-title":"Brain"},{"key":"BFnrdp201556_CR98","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","volume":"61","author":"H Hampel","year":"2004","unstructured":"Hampel, H. et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry 61, 95\u2013102 (2004).","journal-title":"Arch. Gen. Psychiatry"},{"key":"BFnrdp201556_CR99","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1159\/000216841","volume":"27","author":"ES Blom","year":"2009","unstructured":"Blom, E. S. et al. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE \u03b54\/\u03b54 genotype. Dement. Geriatr. Cogn. Disord. 27, 458\u2013464 (2009).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"BFnrdp201556_CR100","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1001\/archneur.60.9.1202","volume":"60","author":"A Maddalena","year":"2003","unstructured":"Maddalena, A. et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to \u03b2-amyloid peptide42. Arch. Neurol. 60, 1202\u20131206 (2003).","journal-title":"Arch. Neurol."},{"key":"BFnrdp201556_CR101","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jama.2009.1064","volume":"302","author":"N Mattsson","year":"2009","unstructured":"Mattsson, N. et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385\u2013393 (2009).","journal-title":"JAMA"},{"key":"BFnrdp201556_CR102","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF02815140","volume":"26","author":"K Blennow","year":"1995","unstructured":"Blennow, K. et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 26, 231\u2013245 (1995).","journal-title":"Mol. Chem. Neuropathol."},{"key":"BFnrdp201556_CR103","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.neuint.2009.02.017","volume":"55","author":"K Koopman","year":"2009","unstructured":"Koopman, K. et al. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P . Neurochem. Int. 55, 214\u2013218 (2009).","journal-title":"Neurochem. Int."},{"key":"BFnrdp201556_CR104","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/archgenpsychiatry.2011.155","volume":"69","author":"P Buchhave","year":"2012","unstructured":"Buchhave, P. et al. Cerebrospinal fluid levels of \u03b2-amyloid 1\u201342, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch. Gen. Psychiatry 69, 98\u2013106 (2012).","journal-title":"Arch. Gen. Psychiatry"},{"key":"BFnrdp201556_CR105","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1212\/WNL.0b013e3182704056","volume":"79","author":"IA van Rossum","year":"2012","unstructured":"van Rossum, I. A. et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology 79, 1809\u20131816 (2012).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR106","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1212\/WNL.0b013e3182918ca6","volume":"80","author":"CM Roe","year":"2013","unstructured":"Roe, C. M. et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 80, 1784\u20131791 (2013).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR107","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000068478","volume":"15","author":"I Skoog","year":"2003","unstructured":"Skoog, I. et al. Cerebrospinal fluid \u03b2-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement. Geriatr. Cogn. Disord. 15, 169\u2013176 (2003).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"BFnrdp201556_CR108","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1006\/neur.1995.0052","volume":"4","author":"I Skoog","year":"1995","unstructured":"Skoog, I. et al. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegeneration 4, 433\u2013442 (1995).","journal-title":"Neurodegeneration"},{"key":"BFnrdp201556_CR109","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1136\/jnnp.2006.100529","volume":"78","author":"DR Gustafson","year":"2007","unstructured":"Gustafson, D. R., Skoog, I., Rosengren, L., Zetterberg, H. & Blennow, K. Cerebrospinal fluid \u03b2-amyloid 1\u201342 concentration may predict cognitive decline in older women. J. Neurol. Neurosurg. Psychiatry 78, 461\u2013464 (2007).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrdp201556_CR110","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1159\/000105017","volume":"24","author":"E Stomrud","year":"2007","unstructured":"Stomrud, E., Hansson, O., Blennow, K., Minthon, L. & Londos, E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement. Geriatr. Cogn. Disord. 24, 118\u2013124 (2007).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"BFnrdp201556_CR111","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jalz.2012.08.004","volume":"9","author":"AC van Harten","year":"2013","unstructured":"van Harten, A. C. et al. Cerebrospinal fluid A\u03b242 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement. 9, 481\u2013487 (2013).","journal-title":"Alzheimers Dement."},{"key":"BFnrdp201556_CR112","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1212\/01.wnl.0000303973.71803.81","volume":"71","author":"JM Ringman","year":"2008","unstructured":"Ringman, J. M. et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71, 85\u201392 (2008).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000335729","volume":"33","author":"JM Ringman","year":"2012","unstructured":"Ringman, J. M. et al. Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 33, 1\u20135 (2012).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"BFnrdp201556_CR114","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen, R. C. et al. Alzheimer's Disease Neuroimaging Initiative (ADNI) clinical characterization. Neurology 74, 201\u2013209 (2010).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR115","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack, C. R. Jr et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119\u2013128 (2010).","journal-title":"Lancet Neurol."},{"key":"BFnrdp201556_CR116","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00401-013-1157-y","volume":"126","author":"GG Kovacs","year":"2013","unstructured":"Kovacs, G. G. et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol. 126, 365\u2013384 (2013).","journal-title":"Acta Neuropathol."},{"key":"BFnrdp201556_CR117","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1017\/cjn.2014.15","volume":"41","author":"ER Zimmer","year":"2014","unstructured":"Zimmer, E. R., Leuzy, A., Gauthier, S. & Rosa-Neto, P. Developments in tau PET imaging. Can. J. Neurol. Sci. 41, 547\u2013553 (2014).","journal-title":"Can. J. Neurol. Sci."},{"key":"BFnrdp201556_CR118","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1750-1326-9-53","volume":"9","author":"A Brinkmalm","year":"2014","unstructured":"Brinkmalm, A. et al. SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Mol. Neurodegener. 9, 53 (2014).","journal-title":"Mol. Neurodegener."},{"key":"BFnrdp201556_CR119","doi-asserted-by":"publisher","unstructured":"Kvartsberg, H. et al. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement. http:\/\/dx.doi.org\/10.1016\/j.jalz.2014.10.009 (2014).","DOI":"10.1016\/j.jalz.2014.10.009"},{"key":"BFnrdp201556_CR120","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/nrd3115","volume":"9","author":"H Hampel","year":"2010","unstructured":"Hampel, H. et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 9, 560\u2013574 (2010).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFnrdp201556_CR121","doi-asserted-by":"publisher","first-page":"16507","DOI":"10.1523\/JNEUROSCI.3647-11.2011","volume":"31","author":"PC May","year":"2011","unstructured":"May, P. C. et al. Robust central reduction of amyloid-\u03b2 in humans with an orally available, non-peptidic \u03b2-secretase inhibitor. J. Neurosci. 31, 16507\u201316516 (2011).","journal-title":"J. Neurosci."},{"key":"BFnrdp201556_CR122","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/npp.2013.154","volume":"39","author":"K Blennow","year":"2014","unstructured":"Blennow, K., Hampel, H. & Zetterberg, H. Biomarkers in amyloid-\u03b2 immunotherapy trials in Alzheimer's disease. Neuropsychopharmacology 39, 189\u2013201 (2014).","journal-title":"Neuropsychopharmacology"},{"key":"BFnrdp201556_CR123","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","volume":"69","author":"K Blennow","year":"2012","unstructured":"Blennow, K. et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch. Neurol. 69, 1002\u20131010 (2012).","journal-title":"Arch. Neurol."},{"key":"BFnrdp201556_CR124","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jalz.2013.01.013","volume":"10","author":"K Henriksen","year":"2014","unstructured":"Henriksen, K. et al. The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement. 10, 115\u2013131 (2014).","journal-title":"Alzheimers Dement."},{"key":"BFnrdp201556_CR125","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1001\/archneur.57.1.100","volume":"57","author":"PD Mehta","year":"2000","unstructured":"Mehta, P. D. et al. Plasma and cerebrospinal fluid levels of amyloid \u03b2 proteins 1\u201340 and 1\u201342 in Alzheimer disease. Arch. Neurol. 57, 100\u2013105 (2000).","journal-title":"Arch. Neurol."},{"key":"BFnrdp201556_CR126","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(12)70228-4","volume":"11","author":"EM Reiman","year":"2012","unstructured":"Reiman, E. M. et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case\u2013control study. Lancet Neurol. 11, 1048\u20131056 (2012).","journal-title":"Lancet Neurol."},{"key":"BFnrdp201556_CR127","doi-asserted-by":"publisher","first-page":"111cm33","DOI":"10.1126\/scitranslmed.3002609","volume":"3","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A., Jack, C. R. Jr & Aisen, P. S. Testing the right target and right drug at the right stage. Sci. Transl. Med. 3, 111cm33 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnrdp201556_CR128","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody, R. S. et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 311\u2013321 (2014). One of many \u2018failed\u2019 Phase III studies that contains evidence of some efficacy, which requires further study in biomarker-defined Alzheimer's disease.","journal-title":"N. Engl. J. Med."},{"key":"BFnrdp201556_CR129","unstructured":"Hoffmann-La Roche. A study of gantenerumab in patients with mild Alzheimer disease. ClinicalTrials.gov[online], (2014)."},{"key":"BFnrdp201556_CR130","unstructured":"Genentech, Inc. A study of crenezumab in patients with mild to moderate Alzheimer disease (AD). ClinicalTrials.gov[online], (2015)."},{"key":"BFnrdp201556_CR131","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue, M. C. et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol. 71, 961\u2013970 (2014).","journal-title":"JAMA Neurol."},{"key":"BFnrdp201556_CR132","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1001\/jamaneurol.2014.3375","volume":"72","author":"RE Amariglio","year":"2015","unstructured":"Amariglio, R. E. et al. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: The Alzheimer's Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol. 72, 446\u2013454 (2015).","journal-title":"JAMA Neurol."},{"key":"BFnrdp201556_CR133","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/alzrt213","volume":"5","author":"KL Moulder","year":"2013","unstructured":"Moulder, K. L. et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res. Ther. 5, 48 (2013).","journal-title":"Alzheimers Res. Ther."},{"key":"BFnrdp201556_CR134","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nrneurol.2013.107","volume":"9","author":"JB Langbaum","year":"2013","unstructured":"Langbaum, J. B. et al. Ushering in the study and treatment of preclinical Alzheimer disease. Nat. Rev. Neurol. 9, 371\u2013381 (2013).","journal-title":"Nat. Rev. Neurol."},{"key":"BFnrdp201556_CR135","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.coph.2013.12.002","volume":"14","author":"AD Roses","year":"2014","unstructured":"Roses, A. D. et al. New applications of disease genetics and pharmacogenetics to drug development. Curr. Opin. Pharmacol. 14, 81\u201389 (2014).","journal-title":"Curr. Opin. Pharmacol."},{"key":"BFnrdp201556_CR136","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jamaneurol.2014.2031","volume":"71","author":"EC Mormino","year":"2014","unstructured":"Mormino, E. C. et al. Synergistic effect of \u03b2-amyloid and neurodegeneration on cognitive decline in clinically normal individuals. JAMA Neurol. 71, 1379\u20131385 (2014).","journal-title":"JAMA Neurol."},{"key":"BFnrdp201556_CR137","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40262-013-0038-9","volume":"52","author":"M Noetzli","year":"2013","unstructured":"Noetzli, M. & Eap, C. B. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin. Pharmacokinet. 52, 225\u2013241 (2013).","journal-title":"Clin. Pharmacokinet."},{"key":"BFnrdp201556_CR138","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","volume":"24","author":"CG Parsons","year":"2013","unstructured":"Parsons, C. G., Danysz, W., Dekundy, A. & Pulte, I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotox. Res. 24, 358\u2013369 (2013).","journal-title":"Neurotox. Res."},{"key":"BFnrdp201556_CR139","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"PN Tariot","year":"2004","unstructured":"Tariot, P. N. et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291, 317\u2013324 (2004).","journal-title":"JAMA"},{"key":"BFnrdp201556_CR140","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jalz.2012.01.002","volume":"9","author":"SD Rountree","year":"2013","unstructured":"Rountree, S. D., Atri, A., Lopez, O. L. & Doody, R. S. Effectiveness of antidementia drugs in delaying Alzheimer's disease progression. Alzheimers Dement. 9, 338\u2013345 (2013).","journal-title":"Alzheimers Dement."},{"key":"BFnrdp201556_CR141","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/gps.1402","volume":"21","author":"A Takeda","year":"2006","unstructured":"Takeda, A. et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Int. J. Geriatr. Psychiatry 21, 17\u201328 (2006).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"BFnrdp201556_CR142","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3233\/JAD-122140","volume":"35","author":"SG Di Santo","year":"2013","unstructured":"Di Santo, S. G., Prinelli, F., Adorni, F., Caltagirone, C. & Musicco, M. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. J. Alzheimers Dis. 35, 349\u2013361 (2013).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrdp201556_CR143","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2217\/cpr.12.3","volume":"9","author":"P Thaipisuttikul","year":"2012","unstructured":"Thaipisuttikul, P. & Galvin, J. E. Use of medical foods and nutritional approaches in the treatment of Alzheimer's disease. Clin. Pract. (Lond.) 9, 199\u2013209 (2012).","journal-title":"Clin. Pract. (Lond.)"},{"key":"BFnrdp201556_CR144","unstructured":"U.S. Food and Drug Administration. Draft Guidance for Industry: frequently asked questions about medical foods. FDA[online], (2013)."},{"key":"BFnrdp201556_CR145","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.clinthera.2007.10.012","volume":"29","author":"Y Sun","year":"2007","unstructured":"Sun, Y., Lu, C. J., Chien, K. L., Chen, S. T. & Chen, R. C. Efficacy of multivitamin supplementation containing vitamins B6 and B12 and folic acid as adjunctive treatment with a cholinesterase inhibitor in Alzheimer's disease: a 26-week, randomized, double-blind, placebo-controlled study in Taiwanese patients. Clin. Ther. 29, 2204\u20132214 (2007).","journal-title":"Clin. Ther."},{"key":"BFnrdp201556_CR146","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2013.282834","volume":"311","author":"MW Dysken","year":"2014","unstructured":"Dysken, M. W. et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 311, 33\u201344 (2014).","journal-title":"JAMA"},{"key":"BFnrdp201556_CR147","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa050151","volume":"352","author":"RC Petersen","year":"2005","unstructured":"Petersen, R. C. et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352, 2379\u20132388 (2005).","journal-title":"N. Engl. J. Med."},{"key":"BFnrdp201556_CR148","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.293.11.1338","volume":"293","author":"E Lonn","year":"2005","unstructured":"Lonn, E. et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293, 1338\u20131347 (2005).","journal-title":"JAMA"},{"key":"BFnrdp201556_CR149","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jamda.2013.01.014","volume":"14","author":"R Shah","year":"2013","unstructured":"Shah, R. The role of nutrition and diet in Alzheimer disease: a systematic review. J. Am. Med. Dir. Assoc. 14, 398\u2013402 (2013).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"BFnrdp201556_CR150","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3233\/JAD-2012-121003","volume":"33","author":"C Echavarri","year":"2013","unstructured":"Echavarri, C. et al. Neuropsychiatric symptoms in Alzheimer's disease and vascular dementia. J. Alzheimers Dis. 33, 715\u2013721 (2013).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrdp201556_CR151","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3233\/JAD-131850","volume":"40","author":"H Brodaty","year":"2014","unstructured":"Brodaty, H., Connors, M. H., Xu, J., Woodward, M. & Ames, D. Predictors of institutionalization in dementia: a three year longitudinal study. J. Alzheimers Dis. 40, 221\u2013226 (2014).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrdp201556_CR152","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/13854046.2013.876101","volume":"28","author":"LA Rog","year":"2014","unstructured":"Rog, L. A. et al. The independent contributions of cognitive impairment and neuropsychiatric symptoms to everyday function in older adults. Clin. Neuropsychol. 28, 215\u2013236 (2014).","journal-title":"Clin. Neuropsychol."},{"key":"BFnrdp201556_CR153","doi-asserted-by":"publisher","first-page":"889","DOI":"10.4088\/JCP.v69n0602","volume":"69","author":"C Salzman","year":"2008","unstructured":"Salzman, C. et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J. Clin. Psychiatry 69, 889\u2013898 (2008).","journal-title":"J. Clin. Psychiatry"},{"key":"BFnrdp201556_CR154","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s11136-011-0044-z","volume":"21","author":"BS Black","year":"2012","unstructured":"Black, B. S. et al. Quality of life of community-residing persons with dementia based on self-rated and caregiver-rated measures. Qual. Life Res. 21, 1379\u20131389 (2012).","journal-title":"Qual. Life Res."},{"key":"BFnrdp201556_CR155","doi-asserted-by":"publisher","first-page":"541","DOI":"10.5014\/ajot.2011.002634","volume":"65","author":"A Thinnes","year":"2011","unstructured":"Thinnes, A. & Padilla, R. Effect of educational and supportive strategies on the ability of caregivers of people with dementia to maintain participation in that role. Am. J. Occup. Ther. 65, 541\u2013549 (2011).","journal-title":"Am. J. Occup. Ther."},{"key":"BFnrdp201556_CR156","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.pop.2011.03.006","volume":"38","author":"D Lussier","year":"2011","unstructured":"Lussier, D., Bruneau, M. A. & Villalpando, J. M. Management of end-stage dementia. Prim. Care 38, 247\u2013264 (2011).","journal-title":"Prim. Care"},{"key":"BFnrdp201556_CR157","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000320588","volume":"30","author":"S Bhattacharya","year":"2010","unstructured":"Bhattacharya, S., Vogel, A., Hansen, M. L., Waldorff, F. B. & Waldemar, G. Generic and disease-specific measures of quality of life in patients with mild Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 30, 327\u2013333 (2010).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"BFnrdp201556_CR158","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1017\/S1041610212001081","volume":"24","author":"M Gomez-Gallego","year":"2012","unstructured":"Gomez-Gallego, M., Gomez-Amor, J. & Gomez-Garcia, J. Determinants of quality of life in Alzheimer's disease: perspective of patients, informal caregivers, and professional caregivers. Int. Psychogeriatr. 24, 1805\u20131815 (2012).","journal-title":"Int. Psychogeriatr."},{"key":"BFnrdp201556_CR159","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1017\/S1041610211002493","volume":"24","author":"PR Bosboom","year":"2012","unstructured":"Bosboom, P. R., Alfonso, H., Eaton, J. & Almeida, O. P. Quality of life in Alzheimer's disease: different factors associated with complementary ratings by patients and family carers. Int. Psychogeriatr. 24, 708\u2013721 (2012).","journal-title":"Int. Psychogeriatr."},{"key":"BFnrdp201556_CR160","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/gps.1075","volume":"19","author":"RE Ready","year":"2004","unstructured":"Ready, R. E., Ott, B. R. & Grace, J. Patient versus informant perspectives of quality of life in mild cognitive impairment and Alzheimer's disease. Int. J. Geriatr. Psychiatry 19, 256\u2013265 (2004).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"BFnrdp201556_CR161","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/WAD.0000000000000050","volume":"29","author":"C Zucchella","year":"2014","unstructured":"Zucchella, C., Bartolo, M., Bernini, S., Picascia, M. & Sinforiani, E. Quality of life in Alzheimer disease: a comparison of patients' and caregivers' points of view. Alzheimer Dis. Assoc. Disord. 29, 50\u201354 (2014).","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"BFnrdp201556_CR162","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/psyg.12094","volume":"15","author":"I Abdollahpour","year":"2014","unstructured":"Abdollahpour, I., Nedjat, S., Salimi, Y., Noroozian, M. & Majdzadeh, R. Which variable is the strongest adjusted predictor of quality of life in caregivers of patients with dementia? Psychogeriatrics 15, 51\u201357 (2014).","journal-title":"Psychogeriatrics"},{"key":"BFnrdp201556_CR163","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3233\/JAD-140342","volume":"43","author":"MF Sousa","year":"2015","unstructured":"Sousa, M. F. et al. Awareness of disease is different for cognitive and functional aspects in mild Alzheimer's disease: a one-year observation study. J. Alzheimers Dis. 43, 905\u2013913 (2015).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrdp201556_CR164","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1590\/0004-282X20140155","volume":"72","author":"RL Santos","year":"2014","unstructured":"Santos, R. L. et al. Caregivers' quality of life in mild and moderate dementia. Arq. Neuropsiquiatr. 72, 931\u2013937 (2014).","journal-title":"Arq. Neuropsiquiatr."},{"key":"BFnrdp201556_CR165","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/00006842-200205000-00016","volume":"64","author":"RG Logsdon","year":"2002","unstructured":"Logsdon, R. G., Gibbons, L. E., McCurry, S. M. & Teri, L. Assessing quality of life in older adults with cognitive impairment. Psychosom. Med. 64, 510\u2013519 (2002).","journal-title":"Psychosom. Med."},{"key":"BFnrdp201556_CR166","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1212\/WNL.57.3.481","volume":"57","author":"RC Mohs","year":"2001","unstructured":"Mohs, R. C. et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57, 481\u2013488 (2001).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR167","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","volume":"57","author":"JS Street","year":"2000","unstructured":"Street, J. S. et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch. Gen. Psychiatry 57, 968\u2013976 (2000).","journal-title":"Arch. Gen. Psychiatry"},{"key":"BFnrdp201556_CR168","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1001\/jama.1996.03540210033030","volume":"276","author":"MS Mittelman","year":"1996","unstructured":"Mittelman, M. S., Ferris, S. H., Shulman, E., Steinberg, G. & Levin, B. A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. JAMA 276, 1725\u20131731 (1996).","journal-title":"JAMA"},{"key":"BFnrdp201556_CR169","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1056\/NEJMoa0809578","volume":"361","author":"RC Green","year":"2009","unstructured":"Green, R. C. et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N. Engl. J. Med. 361, 245\u2013254 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrdp201556_CR170","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1212\/WNL.0b013e3182a55f4a","volume":"81","author":"MB Shulman","year":"2013","unstructured":"Shulman, M. B., Harkins, K., Green, R. C. & Karlawish, J. Using AD biomarker research results for clinical care: a survey of ADNI investigators. Neurology 81, 1114\u20131121 (2013).","journal-title":"Neurology"},{"key":"BFnrdp201556_CR171","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody, R. S. et al. A Phase 3 trial of semagacestat for treatment of Alzheimer's disease. N. Engl. J. Med. 369, 341\u2013350 (2013).","journal-title":"N. Engl. J. Med."},{"key":"BFnrdp201556_CR172","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-50703-8","volume-title":"Histopathologie des Nervensystems","author":"W Spielmeyer","year":"1922","unstructured":"Spielmeyer, W. Histopathologie des Nervensystems (Julius Springer, 1922)."},{"key":"BFnrdp201556_CR173","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","volume":"18","author":"H Braak","year":"1997","unstructured":"Braak, H. & Braak, E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18, 351\u2013357 (1997).","journal-title":"Neurobiol. Aging"},{"key":"BFnrdp201556_CR174","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrn2977","volume":"12","author":"A Thathiah","year":"2011","unstructured":"Thathiah, A. & De Strooper, B. The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nat. Rev. Neurosci. 12, 73\u201387 (2011).","journal-title":"Nat. Rev. Neurosci."},{"key":"BFnrdp201556_CR175","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3233\/JAD-2012-121189","volume":"31","author":"P Scheltens","year":"2012","unstructured":"Scheltens, P. et al. Efficacy of souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J. Alzheimers Dis. 31, 225\u2013236 (2012).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrdp201556_CR176","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","volume":"14","author":"LS Schneider","year":"2006","unstructured":"Schneider, L. S., Dagerman, K. & Insel, P. S. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am. J. Geriatr. Psychiatry 14, 191\u2013210 (2006).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"BFnrdp201556_CR177","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings, J. et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383, 533\u2013540 (2014).","journal-title":"Lancet"},{"key":"BFnrdp201556_CR178","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2014.93","volume":"311","author":"AP Porsteinsson","year":"2014","unstructured":"Porsteinsson, A. P. et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 311, 682\u2013691 (2014).","journal-title":"JAMA"},{"key":"BFnrdp201556_CR179","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/JGP.0b013e3181c796eb","volume":"18","author":"PB Rosenberg","year":"2010","unstructured":"Rosenberg, P. B. et al. Sertraline for the treatment of depression in Alzheimer disease. Am. J. Geriatr. Psychiatry 18, 136\u2013145 (2010).","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"BFnrdp201556_CR180","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1017\/S1041610213001762","volume":"26","author":"KL Lanctot","year":"2014","unstructured":"Lanctot, K. L. et al. Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. Int. Psychogeriatr. 26, 239\u2013246 (2014).","journal-title":"Int. Psychogeriatr."},{"key":"BFnrdp201556_CR181","first-page":"CD009178","volume":"3","author":"J McCleery","year":"2014","unstructured":"McCleery, J., Cohen, D. A. & Sharpley, A. L. Pharmacotherapies for sleep disturbances in Alzheimer's disease. Cochrane Database Syst. Rev. 3, CD009178 (2014).","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Nature Reviews Disease Primers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nrdp201556.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrdp201556","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nrdp201556.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T21:31:39Z","timestamp":1748640699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrdp201556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,15]]},"references-count":181,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,17]]}},"alternative-id":["BFnrdp201556"],"URL":"https:\/\/doi.org\/10.1038\/nrdp.2015.56","relation":{},"ISSN":["2056-676X"],"issn-type":[{"value":"2056-676X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,15]]},"assertion":[{"value":"15 October 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.L.M. has provided consultation to Eli Lilly, Actinogen and Prana Biotechnology. He has stock ownership in Prana Biotechnology. R.B. has provided consultation to FORUM, Merck, Roche, Sanofi, Boehringer Ingelheim and Eli Lilly. He currently consults and owns stock in C2N Diagnostics, which he co-founded. He also receives research support from Eli Lilly, Roche, Merck and the Dominantly Inherited Alzheimer Network (DIAN) Pharma Consortium (comprising Amgen, Biogen Idec, Eisai, FORUM, Genentech, Janssen, Lilly, Roche and Sanofi). K.B. has served on advisory boards for Amgen, Eli Lilly, IBL International, Novartis, Roche Diagnostics and Sanofi-Aventis. C.C.R. has received research grants from GE Healthcare, Avid Radiopharmaceuticals, Primal, AstraZeneca and Navidea in the past 2 years. R.A.S. has served as a consultant for Janssen, Genentech, ISIS Pharmaceuticals and Roche. She receives research support from Eli Lilly and Janssen. J.L.C. has provided consultation to AbbVie, Acadia, Actinogen, ADAMAS, Alzheon, Anavex, Avanir, Biogen Idec, Biotie, Boehinger Ingelheim, Chase, Eisai, FORUM, Genentech, Grifols, Intracellular Therapies, Eli Lilly, Lundbeck, Merck, Neurotrope, Novartis, Nutricia, Otsuka, Pfizer, Resverlogix, Roche, Roivant, Suven, Takeda and Toyoma companies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15056"}}